期刊文献+

乳腺癌新辅助化疗及微转移检测 被引量:2

Detecting of neoadjuvant chemotherapy and micrometastasis of breast cancer
原文传递
导出
摘要 对于乳腺癌外周血微转移,常规检查难以发现。近年来,应用免疫组化及分子生物学等方法联合检测微转移相关指标,提高了乳腺癌微转移的检出率。随着研究的不断深入,及早发现乳腺癌外周血微转移并利用新辅助化疗手段,对研究其预后与化疗疗效之间的关系具有重要意义。 The routine examination is hard to detect micrometastasis cell in peripheral blood of breast cancer. The correlated indexes are detected by immunohistochemistry(IHC) and molecular biology for breast cancer of micrometastasis, the positive rate are raised. Find micrometastasis cell early in peripheral blood and carry out neoadjuvant chemotherapy, It is important for studing the relationship between prognosis and therapeutic effect in breast cancer.
作者 和钢 张乐鸣
出处 《国际肿瘤学杂志》 CAS 2006年第10期769-771,共3页 Journal of International Oncology
基金 浙江省科技计划基金资助项目(2006C33036)
关键词 乳腺肿瘤 肿瘤转移 肿瘤辅助疗法 逆转录聚合酶链反应 Breast cancer Neoplasm metastasis Neoadjuvant therapy Reverse transcriptasepolymerase chain reaction
  • 相关文献

参考文献1

二级参考文献15

  • 1Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis.Cell, 1990,61 : 759-767.
  • 2Silva JM, Gonzalez R, Dominguez G, et al. Tp53 gene mutations in plasma DNA of cancer patients. Genes Chromosomes Cancer, 1999, 24:160-161.
  • 3Silva JM, Dominguez G, Genzalez R, et al. Presence of tumor DNA in plasma of breast cancer patients: clinico-pathological correlation. Cancer Res, 1999, 59: 3252-3256.
  • 4Norberg T, Lenneistand J, Inganas M, et al. Comparison between p53 protein measurements using the lumi-metric immu-as-say and immuhistochemistry with delection of p53 mutations using cDNA sequencing in human breast tumor. Int J Cancer, 1998, 79: 376-383.
  • 5Stroum M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from plasma of cancer patients. Eur J Cancer Clin Oncol, 1987,23: 707-712.
  • 6Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med, 1996, 2:1033-1035.
  • 7Leon SA, Shapiro DM, Sklaroff D, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res, 1977, 37: 646-650.
  • 8Hollstein M, Sidransky D, Vogelstein B, et al. p53 matations in human cancer. Science, 1991, 253: 49-53.
  • 9Linderholm B, Lindh B, Tavelin B, et al. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carci-ma. Int J Cancer, 2000, 89: 51-62.
  • 10Elston CW, Ellis IO. Pathological prog-stic factors in breast cancer, the value of histological grade in breast cancer: experi-ence from a large study with long-term follow-up. Histopathology, 1991, 19: 403-410.

共引文献18

同被引文献13

  • 1张新丽,刘希光,张明宾,李建哲.乳腺癌患者外周血CK19mRNA检测对辅助化疗有效性监测的临床研究[J].泰山医学院学报,2008,29(2):104-106. 被引量:2
  • 2张小萍,王亚娜.我院抗肿瘤药物用药分析[J].中国药物与临床,2005,5(11):861-862. 被引量:1
  • 3孙鹏达,谷洋,王庆国.大肠癌新辅助化疗[J].国际肿瘤学杂志,2006,33(2):151-153. 被引量:10
  • 4Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-1 8. J Nail Cancer Inst Monogr,2001, (30) :96-102.
  • 5Anna F,Jadwiga K,Paulina K, et al. Detection of circulating breast cancer cells in peripheral blood by a two2marker reverse transcriptasepolymerase chain reaction assay. Acta Biochimica Polonica ,2004,5 1 ( 5 ) :747-749.
  • 6De Luca A, Pignata S, Casamassimi A, et al. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clin Cancer Res ,2000,6(4) : 1439-1444.
  • 7Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Mo-lecular detection of cytokeratin-19-positive cells in the peripheral blood pf patients with operable breast cancer: evaluation of their Prognostic significance. J Clin 0ncol,2002,20 (16) : 3404-3412.
  • 8Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin Plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer:results from NSABP B-28 . J Clin Oncol,2005,23(16) :3686-3696.
  • 9Wolmark N,Wang J, Mamounas E,et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr,2001 ,(30):96-102.
  • 10Bartek J, Lukas J. Mammalian G1 and S-phase checkpoints in response to DNA damage. J Curr Opin Cell Biol,2001,13(6):738- 747.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部